A Study to Evaluate the Efficacy and Safety of QL1706 Injection in Patients With Solid Tumors
Status:
Active, not recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
This a multi-center, open-label, non-randomized phaseⅠb trail. The purpose of this study was
to evaluate the efficacy and safety of QL1706 in patients with advanced solid tumors and to
investigate the immunogenicity and pharmacokinetic characteristics of QL1706.